CYSTAGON (cysteamine bitartrate)
ORAL CYSTINOSIS THERAPY, CYSTINE DEPLETING AGENTS · NEPHROPATHIC CYSTINOSIS
Mylan Pharmaceuticals
Drug class
Oral Cystinosis Therapy, Cystine Depleting Agents
Oral cystinosis therapy, cystine-depleting agents comprise a specialized therapeutic class primarily represented by systemic formulations of cysteamine, including immediate-release and delayed-release cysteamine bitartrate. Read more about Oral Cystinosis Therapy, Cystine Depleting Agents
3 drugs in this class 2 manufacturers
Drugs in Oral Cystinosis Therapy, Cystine Depleting Agents
PROCYSBI (cysteamine bitartrate)
ORAL CYSTINOSIS THERAPY, CYSTINE DEPLETING AGENTS · NEPHROPATHIC CYSTINOSIS
HORIZON/AMGEN
PROCYSBI (cysteamine bitartrate)
ORAL CYSTINOSIS THERAPY, CYSTINE DEPLETING AGENTS · NEPHROPATHIC CYSTINOSIS
HORIZON/AMGEN
Filter & compare in the drug finder →
Opens the drug finder with Oral Cystinosis Therapy, Cystine Depleting Agents preselected. Add indication or manufacturer filters there.
Oral cystinosis therapy, cystine-depleting agents comprise a specialized therapeutic class primarily represented by systemic formulations of cysteamine, including immediate-release and delayed-release cysteamine bitartrate.
These medications function intracellularly by entering lysosomes and undergoing a thiol-disulfide exchange reaction with accumulated cystine, cleaving it into cysteine and a cysteine-cysteamine mixed disulfide.
These resultant molecules readily exit lysosomes via alternative amino acid export pathways, effectively bypassing the defective cystinosin transporter.
Clinically, these oral agents are indicated for the lifelong management of nephropathic cystinosis to decrease systemic intracellular cystine accumulation, delay renal failure, and mitigate extrarenal organ complications.
-
goodrx.com
Oral cystinosis therapy, cystine-depleting agents comprise a specialized therapeutic class primarily represented by systemic formulations of cysteamine, including immediate-release and delayed-release cysteamine bitartrate Clinically, these oral agents are indicated for the lifelong management of nephropathic cystinosis to decrease systemic intracellular cystine accumulation, delay renal failure, and mitigate extrarenal organ complications
-
fda.gov
Oral cystinosis therapy, cystine-depleting agents comprise a specialized therapeutic class primarily represented by systemic formulations of cysteamine, including immediate-release and delayed-release cysteamine bitartrate
-
understandingcystinosis.com
These medications function intracellularly by entering lysosomes and undergoing a thiol-disulfide exchange reaction with accumulated cystine, cleaving it into cysteine and a cysteine-cysteamine mixed disulfide These resultant molecules readily exit lysosomes via alternative amino acid export pathways, effectively bypassing the defective cystinosin transporter
-
nih.gov
These medications function intracellularly by entering lysosomes and undergoing a thiol-disulfide exchange reaction with accumulated cystine, cleaving it into cysteine and a cysteine-cysteamine mixed disulfide
-
frontiersin.org
These resultant molecules readily exit lysosomes via alternative amino acid export pathways, effectively bypassing the defective cystinosin transporter
-
nih.gov
Clinically, these oral agents are indicated for the lifelong management of nephropathic cystinosis to decrease systemic intracellular cystine accumulation, delay renal failure, and mitigate extrarenal organ complications
-
fda.gov
Clinically, these oral agents are indicated for the lifelong management of nephropathic cystinosis to decrease systemic intracellular cystine accumulation, delay renal failure, and mitigate extrarenal organ complications
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.